Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(11%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_2
3
33%
Ph phase_3
2
22%
Ph not_applicable
1
11%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
2(25.0%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(3)

Detailed Status

unknown3
Not yet recruiting2
Completed2
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 23 (37.5%)
Phase 32 (25.0%)
N/A1 (12.5%)

Trials by Status

terminated111%
not_yet_recruiting222%
unknown333%
recruiting111%
completed222%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9